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) is a labile metabolite of arachi-
donic acid that has potent biological effects. Its actions are
mediated by G protein–coupled thromboxane-prostanoid
(TP) receptors. TP receptors have been implicated in the
pathogenesis of cardiovascular diseases. To investigate the
physiological functions of TP receptors, we generated TP











produce and survive in expected numbers, and their major
organ systems are normal. Thromboxane agonist binding





















 mice and their platelets do not





sponses after collagen stimulation are also delayed, al-
though ADP-stimulated aggregation is normal. Infusion of
the TP receptor agonist U-46619 causes transient increases
in blood pressure followed by cardiovascular collapse in























mice are also resistant to arachidonic
acid–induced shock, although arachidonic acid signifi-






















mice have a mild bleeding disorder and altered vascu-




 and arachidonic acid. Our studies







































 is a biologically active lipid mediator that is produced
by the metabolism of arachidonic acid through the cyclooxyge-


















 functions primarily as an auto-
coid and its actions are limited to tissues in proximity to the





 contributes to vascular homeostasis through its actions





 appears to regulate renal hemodynamics and so-




 may also play a role in the immune
system through effects on thymic cell selection (9) and through





 synthesis and actions has been implicated in the
pathogenesis of a number of disease states including cardiovas-
cular disease (12), asthma (13), eclampsia (14, 15), and a vari-
ety of kidney diseases (3, 16–18).




 are mediated by cell surface receptors





 which are members of the G protein–coupled receptor
superfamily (19). TP receptors are expressed in a number of
tissues including thymus, platelets, lung, kidney, spleen, and
placenta (20, 21). While the thromboxane receptors that have
been cloned to date demonstrate substantial homology (20–
22), earlier pharmacological studies had suggested heterogene-
ity of function and agonist binding characteristics (23–27). For
example, in mesangial cells, vascular smooth muscle cells, and
platelets, activation of the thromboxane receptor is associated
with rapid increases in intracellular calcium that are dependent
on phospholipase C activation (5, 25, 28, 29), whereas in mac-
rophages the TP receptor may be linked to adenyl cyclase (30).
A structural basis for these differences in second messenger
coupling and ligand binding affinities has not been determined
clearly. It has been hypothesized that these differences in bio-
chemical properties might be mediated by TP receptor iso-
forms encoded by distinct genes. However, so far only a single




) has been identified (31).




 in physiological pro-
cesses have relied primarily on pharmacological inhibitors of
thromboxane synthase or thromboxane receptor antagonists.
These pharmacological approaches have inherent limitations
related to the potency, specificity, and dosage of individual
agents. To further examine in vivo functions of TP receptors,
we used gene targeting to produce TP receptor–deficient mice.
Our studies suggest a key role for the TP receptor in hemosta-
sis and regulation of certain vascular responses. In addition,















gene, a partial complementary DNA probe was prepared
by PCR after reverse transcription of total RNA isolated from mouse
lung. The PCR primer sequences were derived from the published se-
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). The resulting 438-bp partial cDNA fragment
corresponds to the region of the TP receptor protein extending from
the second extracellular loop through the proximal half of the intra-
cellular cytoplasmic tail.
This probe was used to screen a complete BamHI-digested ge-
nomic library constructed in the lambda DashII phage vector using
genomic DNA isolated from the mouse ES cell line E14tg2a. Hybrid-
izing phages were purified and a restriction map of the genomic DNA




. To construct the tar-
geting vector, an 8-kb KpnI fragment containing exons 2 and 3 of the
TP receptor and encompassing all of the protein coding sequences
was subcloned into pBluescript KS (Stratagene Inc., La Jolla, CA). A
neomycin resistance gene driven by the phosphoglycerol kinase
(PGK) promoter was inserted into a unique SfiI site near the proxi-




 gene in the third transmembrane domain. ES cells were grown,
transformed, and screened using standard methodologies (32). Colo-
nies in which the plasmid had integrated by homologous recombina-




 probe shown in
Fig. 1.
 
Generation of Tp-deficient mice.
 
Targeted ES cells were intro-
duced into C57BL/6 mouse blastocysts using standard techniques









The Jackson Laboratory, Bar Harbor, ME) or 129/SvEv females to
identify germline competent chimeras that were capable of transfer-





allele was detected in offspring of these crosses by South-
ern blot analysis of genomic DNA isolated from tail biopsies as
shown in Fig. 1. Offspring carrying the mutant allele were inter-




































 mice and RNA was extracted from the tissues
using a commercially available reagent (Tri-reagent; Sigma Chemical




g of total RNA per sample was denatured
and size-fractionated in glyoxal-dimethyl sulfoxide gels and trans-





fragment that had been generated by RT-PCR (see above) was sub-
cloned into pBluescript KS (Stratagene, La Jolla, CA) and sequenced
to determine its orientation. The plasmid was then linearized and




P-CTP labeled riboprobe (MAXI-
script; Ambion, Inc., Austin, TX). The membranes were hybridized
at high stringency and after washing, the filters were exposed to Kodak
















 receptor in thymocytes




I-labeled thromboxane receptor agonist
IBOP (a gift from Perry Haluska) (34) [1S-(1 alpha,2 beta(5Z),3 al-
pha-(1E,3S)4 alpha)-7-(3-(3-hydroxy-4-(p-iodophenoxy)-1-butenyl)-
7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid]. Thymocyte suspen-





































gently grinding the thymus between glass slides. The cells were
washed once in PBS and then resuspended in ice-cold PBS containing






















M) of unlabeled IBOP. The incubation mixtures were filtered
through Whatman GF/C glass fiber filters and the filters were washed




I counts were deter-
mined using a gamma counter. Specific binding was calculated as the
total binding minus background and binding was expressed as a per-









 binding in kidney sections




I-BOP as described previously (27). After




















 mice, the capsule was excised, the tissue was embedded in
O.T.C. compound (Miles, Elkhart, IN), and frozen in liquid nitrogen–





cryostat and thaw-mounted on glass microscope slides (FisherPlus;
Fisher Scientific, Pittsburgh, PA). The mounted tissue sections were
first preincubated in Dulbecco’s PBS, pH 6.5, with 10 mM Tris-HCl,













I-BOP in 10 mM PBS containing 150









M) of unlabeled IBOP were
added to some sections to define nonspecific binding. After incuba-




C, the radioligand binding mixture
was aspirated, and slide-mounted tissues were washed four times for
10 min each with ice-cold Dulbecco’s PBS, pH 6.5, containing 10 mM
Tris-HCl and 0.5% BSA and rinsed twice with ice-cold distilled wa-




C, and then ex-
posed to high-resolution x-ray film (Hyperfilm-betamax; Amersham
International plc, Little Chalfont, Buckinghamshire, UK) for up to 1
wk. Prints were made from the tissue autoradiograms using F5 Ko-




Flow cytometry on splenocytes and thymocytes
was performed as described previously (35). In brief, spleen and thy-




















 mice and cell suspensions
were obtained by gently grinding the tissue between sterile glass

















l aliquots of resuspended cells were in-





and were washed three times in buffer. The mAbs used were: GK 1.5
(anti-CD4), 53-6.7 (anti-CD8), 30-H122 (anti-Thy 1.2) RA36B2 (anti-
B220), and M1/70 (anti-CD11b) (all from PharMingen, San Diego,
CA). An irrelevant isotypic antibody R35-95 (rat IgG2a; PharMin-
gen) was used as a control for nonspecific staining. After final wash-
ing, cells were fixed with PBS containing 2% formalin and were ana-





 (Becton Dickinson, Mountain View, CA). Forward scat-
ter threshold was set to exclude dead cells and debris from acquisi-
Figure 1. Targeted disruption of the mouse Tp gene. (A) The endog-
enous Tp gene locus. Black boxes represent exons while the stippled 
box represents the probe used in Southern blot analysis. B, BamHI; 
K, KpnI; S, SfiI. (B) The Tp targeting vector. (C) The targeted Tp al-
lele. (D) Southern blot analysis of Tp mice. Genomic DNA was iso-
lated from mouse tails, digested with restriction enzyme BamHI, sep-
arated on agarose gels, and transferred to nylon membranes. This 
blot was hybridized to the 32P-labeled DNA probe shown in the fig-
ure. The 11.2-kb band represents the endogenous wild-type Tp allele 










 cells were analyzed for each antibody or antibody
combination.
 
Bleeding time measurement. Bleeding times were assessed in con-
scious mice as described by Dejana et al. (36). The mice were placed into
a restraining device and their tails were secured in a vertical position
throughout the test. An z 3–5-mm segment of the tail was transected
using a disposable scalpel, and the remaining length of tail was immersed
immediately into 378C sterile isotonic saline. Bleeding time was calcu-
lated from the time of tail transection until visible bleeding could no
longer be detected. If active bleeding continued for . 10 min, the ex-
periment was terminated and the bleeding site was cauterized.
Platelet aggregation assays. After anesthesia with isofluorane, z 1
ml of whole blood was removed by cardiac puncture into 10 U of hep-
arin. The heparinized blood was centrifuged at 100 g for 10 min at
room temperature and the platelet-rich plasma (PRP) was removed.
The remaining fractions were centrifuged at 2,400 g and the superna-
tant of platelet-poor plasma (PPP) was reserved. The number of
platelets in the PRP was determined using a hemacytometer and the
volume was adjusted with PPP to achieve a concentration of 3 3 105
platelets/ml. Platelet aggregation was determined by light absorbance
using a platelet aggregation profiler (model PAP-4; Bio/Data Corp.,
Horsham, PA). The baseline was set using PPP, and aggregation of
individual PRP samples was determined after the addition of a series
of compounds. Agents that were used to induce platelet aggregation
included: 20 mM U-46619; (15S)-hydroxy-11,9-(epoxymethano)prosta-
5Z,13E-dienoic acid, a thromboxane receptor agonist (Cayman Chem-
ical Co., Ann Arbor, MI); 4 mM ADP (Sigma Chemical Co., St. Louis,
MO); and collagen reagent 0.05 mg/ml (Sigma Chemical Co.). After
addition of agonist, platelet aggregation was monitored for 5–8 min.
Systolic blood pressure measurements in conscious mice. Systolic
blood pressures were measured in conscious mice using a computer-
ized tail cuff system (Visitech Systems, Cary, NC) that determines
systolic blood pressure using a photoelectric sensor (37). This system
allows pressures to be measured in four mice simultaneously and
minimizes the potential for observer bias. Before the study was initi-
ated, mice were adapted to the apparatus for at least 5 d. The validity
of this system has been established previously (37) and we have dem-
onstrated its correlation with intraarterial pressure measurements in
several experimental systems (38, 39).
Intraarterial blood pressure measurements and assessment of vas-
cular responses to infusion with the TP receptor agonist U-46619 or
arachidonic acid. Tp1/1 and Tp2/2 mice were anesthetized with iso-
fluorane, a short length of polyethylene (PE-50) tubing was placed in
the trachea to facilitate spontaneous ventilation, a flexible plastic
catheter (Micro Renathane, type MRE-040, 0.040 O.D. 3 0.025 I.D.;
Braintree Scientific Co., Braintree, MA) was placed in the carotid ar-
tery to monitor arterial pressure, and a second catheter was placed in
the jugular vein to infuse vasoactive compounds. Intraarterial blood
pressure was recorded continuously through the carotid catheter us-
ing Windaq data acquisition and playback software (Dataq Instru-
ments, Akron, OH) as described previously (39, 40).
After the surgical preparation was completed, the effects of intra-
venous infusions of vasoactive compounds on mean arterial pressure
(MAP) were determined as described previously (39, 40). Beginning
with an equilibration period of 5–10 min, blood pressure was re-
corded continuously for the duration of each experiment at 50 re-
cordings/s. To facilitate their analysis, the data collected from each
animal were compressed to 5 readings/s and the MAP tracings from
animals in each experimental group were integrated and averaged.
Immediately after the equilibration period, the mice first received a
bolus injection of 0.9% sodium chloride solution in a volume (1 ml/g
body wt) that was identical to the subsequent injections. In separate
experiments, mice received either a single 10 mg/kg bolus of arachi-
donic acid (Cayman Chemical Co.) or two consecutive bolus infu-
sions of U-46619 (100 mg/kg and 1 mg/kg; Cayman Chemical Co.)
separated by 5 min.
Data analysis. The values for each parameter within a group are
expressed as the mean6SEM. For comparisons between Tp1/1 and
Tp2/2 groups, statistical significance was assessed using an unpaired t
test. A paired t test was used for comparisons within groups.
Results
Generation of Tp-deficient mice. The gene encoding the TP
receptor was disrupted in the E14Tg2a ES cell line by homolo-
gous recombination with the targeting plasmid shown in Fig. 1.
Sequence analysis of our genomic clone suggested that the or-
ganization of the mouse Tp gene is similar to that described for
the human gene (31) wherein exons 2 and 3 contain the entire
protein coding region. The targeting plasmid was designed to
disrupt the Tp gene by introducing a neomycin resistance cas-
sette into the coding regions of exon 2. Targeted ES cell lines
were identified by Southern analysis and introduced into blas-
tocysts to generate chimeric mice. Chimeras were bred to 129/
SvEv or B6/D2 mice and Tp1/2 offspring carrying the mutant
allele were identified by Southern analysis as shown in Fig. 1,
C and D.
Mice that were homozygous for the targeted mutation
(Tp2/2) were generated by the intercross of Tp heterozygous
animals (Tp1/2). Among the first 124 progeny of these het-
erozygous crosses, 26 (21%) were Tp1/1, 67 (54%) were Tp1/2,
and 31 (25%) were Tp2/2. The number of Tp2/2 animals corre-
sponded to that expected (25%) for simple Mendelian inherit-
ance, suggesting that the absence of the TP receptors does not
adversely affect intrauterine development or perinatal sur-
vival. Furthermore, the Tp2/2 animals could not be distin-
guished from normal littermates by simple observation. Histo-
logical examination of heart, thymus, spleen, small intestine,
lymph nodes, and aorta from the Tp2/2 animals did not reveal
any pathological changes. Since the TP receptor is highly ex-
pressed in placenta (20) and uterus (21), the fertility of Tp2/2
females was also examined. The frequency of productive mat-
ings, gestation, delivery, and care of litters were not different
between Tp1/1 and Tp2/2 females.
TP receptor mRNA expression in mutant mice. To verify that
the targeted mutation introduced into the Tp gene locus re-
sulted in inactivation of the gene, we examined expression of
the TP receptor mRNA in thymus by Northern blot, because
thymus is the tissue with the highest level of the TP receptor
expression. Total RNA was prepared from the thymus of Tp1/1
and Tp2/2 animals and Northern blot analysis was performed
using an antisense riboprobe synthesized from a TP receptor
cDNA template. As shown in Fig. 2, two major bands that hy-
bridized with the Tp probe were detected in RNA prepared
from the thymus of wild-type Tp1/1 mice including the 2-kb
band corresponds to the size of the mouse TP receptor mRNA
(21). Although several aberrant transcripts were observed in
Tp2/2 animals, the 2-kb transcript was not detected.
TXA2 radioligand binding studies in thymocytes from Tp
mutant mice. To verify that the absence of normal TP receptor
mRNA transcripts in Tp2/2 mice was associated with the loss
of functional receptors for TXA2, we examined thromboxane
binding in thymocytes using the TP receptor agonist IBOP. As
shown in Table I, specific 125I-BOP binding was easily detected
in thymocytes from wild-type mice (0.6060.29% specific cpm).
In contrast, specific 125I-BOP binding in thymocytes from TP-
deficient mice does not differ from background (0.0160.01%
specific cpm; P , 0.0008 vs. wild-type).
Thymocyte phenotypes are normal in Tp2/2 mice. Immuno-
histochemical staining of thymus revealed no differences in the
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distribution of T cells (Thy1.21 staining) or specific T cell pop-
ulations (CD41 or CD81) between Tp2/2 and wild-type mice.
FACS® analysis revealed no differences between Tp2/2 and
Tp1/1 mice in the number of single positive, CD41 or CD81, T
cells or double positive, CD41CD81, T cells within the thymus.
In addition, there were no differences in the number of total T
cells, CD41 T cells, CD81 T cells, B cells, or macrophages in
spleen of wild-type and Tp2/2 mice.
TP receptor autoradiography in kidney. In previous stud-
ies, we used receptor autoradiography to visualize the distribu-
tion and characteristics of thromboxane binding sites in mouse
kidney (27). To define the effect of the TP receptor mutation
on renal binding, we performed receptor autoradiography in
Tp1/1 and Tp2/2 mice using the TP receptor agonist 125I-BOP.
Specific 125I-BOP binding sites are present throughout the re-
nal cortex and medulla in Tp1/1 mice (Fig. 3 A). In contrast, no
125I-BOP binding could be detected in kidney sections from
Tp2/2 mice (Fig. 3 C).
Bleeding time assessment in Tp-deficient mice. TXA2 is a po-
tent stimulator of platelet aggregation in vitro (41) and natu-
rally occurring mutations of the Tp gene cause abnormal
bleeding in humans (42). Therefore, we determined bleeding
times in Tp2/2 mice. As shown in Table I, bleeding times aver-
aged 9665 s in conscious, wild-type mice (n 5 11). However,
in the Tp2/2 mice, bleeding times were markedly prolonged
(P , 0.0001 vs. wild-type); all of the Tp-deficient mice contin-
ued to bleed for the entire 10-min observation period (n 5 6).
Because pharmacological antagonism of the TP receptor has
only minimal effects on bleeding time in humans, we also mea-
sured bleeding time in wild-type mice (n 5 6) that had been
pretreated with an intravenous infusion of 10 mg/kg of the TP
receptor antagonist SQ-29,548. Bleeding times were similarly
prolonged (. 10 min in all animals) in these wild-type mice in
which TP receptors were blocked pharmacologically (43).
Platelet aggregation responses in Tp2/2 mice. To examine
platelet function in Tp2/2 mice, we performed a series of plate-
let aggregation studies. As depicted in Fig. 4, the thromboxane
agonist U-46619 induced vigorous aggregation of platelets in
wild-type mice (8165% aggregation) but caused no detectable
aggregation of platelets from Tp2/2 mice (361% aggregation,
P , 0.0001 vs. wild-type). We also tested whether the absence
of TP receptors affected responses to the other platelet ago-
Figure 2. Northern blot analysis of thymic RNA from Tp1/1 and 
Tp2/2 mice. Total RNA was extracted from thymus and 15 mg of total 
RNA/sample was separated on glyoxal/dimethyl sulfoxide agarose 
gels, transferred onto nylon membranes, and then hybridized to a 
32P-labeled antisense riboprobe. (A) Hybridization with the antisense 
TP receptor riboprobe. (B) Hybridization with a b-actin antisense ri-
boprobe to assess equivalency of RNA loading.













% specific counts mmHg mmHg s
Tp1/1 0.6060.29 12165 9364 9668
Tp2/2 0.0160.01* 11463 10064 . 600‡
*P 5 0.0008 vs. Tp1/1, ‡P , 0.0001 vs. Tp1/1.
Figure 3. TP receptor autoradiography using the TP receptor agonist 
125I-BOP. (A) Total 125I-BOP binding in Tp1/1 mouse kidney sections. 
(B) Nonspecific 125I-BOP binding in Tp1/1 mouse kidney sections in 
the presence of excess unlabeled IBOP. (C) Total 125I-BOP binding in 
Tp2/2 mouse kidney sections.
Figure 4. Platelet aggregation induced by the TP receptor agonist 
U-46619 in Tp1/1 and Tp2/2 mice. U-46619 caused rapid aggregation 
of platelets from Tp1/1 mice, but had no discernible effect on plate-
lets from Tp2/2 mice.
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nists. After collagen treatment, the delay period (7967 s) be-
fore platelet aggregation occurred was significantly longer in
Tp2/2 PRP compared with controls (5065 s, P 5 0.0047 vs.
Tp2/2 PRP). However, the maximum aggregation was similar
between the two groups. There was no difference in platelet
aggregation responses induced by addition of ADP to PRP
from Tp1/1 or Tp2/2 mice.
Systolic blood pressure in Tp2/2 mice. Previous studies have
suggested a role for the TP receptors in the regulation of blood
pressure and hemodynamic responses in various models of hy-
pertension, vascular disease, and shock (44). To determine
whether the absence of TP receptors affected blood pressure
homeostasis, we measured systolic blood pressure in conscious
mice using an automated tail cuff system as described previ-
ously (37). Systolic blood pressure tended to be lower in the
Tp2/2 mice (11463 mmHg) than controls (12165 mmHg), but
this difference was not statistically significant. Similarly, MAP
was not different in anesthetized Tp1/1 (9364 mmHg) and
Tp2/2 (10064) mice.
Cardiovascular responses to infusions of a thromboxane re-
ceptor agonist or arachidonic acid. Intravenous administration
of either TP receptor agonist or arachidonic acid causes a syn-
drome of cardiovascular collapse and sudden death associated
with systemic platelet aggregation, pulmonary thrombosis, and
coronary spasm (45). To determine the effects of the Tp muta-
tion on these responses, we first infused successive boluses of
100 mg/kg and 1 mg/kg U-46619 intravenously into anesthe-
tized Tp2/2 and wild-type mice while simultaneously monitor-
ing MAP. As can be seen in Fig. 5, the low dose of U-46619
(0.1 mg/kg) caused a transient rise in blood pressure in wild-
type animals. The maximal increase of 2162 mmHg occurred
60 s after U-46619 infusion and MAP returned to baseline lev-
els after 120 s. The higher dose of thromboxane agonist also
caused a transient, early increase in MAP in Tp1/1 mice. How-
ever, 2–3 min after administration of 1 mg/kg U-46619, MAP
began to drop precipitously in the wild-type animals. This was
followed by rapid hemodynamic collapse. After receiving the
highest dose of U-46619, none of the three Tp1/1 animals sur-
vived beyond 6 min. In contrast, as shown in Fig. 5, U-46619
had no detectable effect on MAP in the Tp2/2 mice. All four
Tp2/2 mice survived to the end of the experiment.
The Tp mutation also caused a substantial alteration in the
hemodynamic responses to arachidonic acid. As depicted in
Fig. 6, MAP began to fall in the wild-type animals within 120 s
after infusion of arachidonic acid. Cardiovascular collapse and
shock rapidly ensued. None of the five Tp1/1 animals survived
beyond 300 s after infusion of the arachidonic acid. As illus-
trated in Fig. 6, arachidonic acid also caused a significant low-
ering of MAP in the Tp2/2 mice. However, while MAP fell by
z 25 mmHg in Tp2/2 mice, the animals remained stable at this
reduced level of MAP through the remainder of the experi-
ment. All five Tp2/2 animals survived to the end of the experi-
ment.
Discussion
To assess the role of the thromboxane receptor in develop-
ment and in the regulation of physiological functions, we used
gene targeting to disrupt the Tp locus. Tp null mutant mice are
born in the expected Mendelian ratios and appear normal and
healthy, suggesting that the TP receptor does not have a
unique role in development or in promoting perinatal survival.
TP receptors are expressed at high levels in the placenta and
uterus and it has been suggested that these receptors may play
a functional role in pregnancy, gestation, or delivery. How-
ever, we found that Tp2/2 females have normal frequency of
productive matings, viable, normal size litters, and provide
normal care for their offspring. Thus, if the TP receptor is in-
volved in perinatal processes, it is not indispensable.
One of the tissues with the highest level of TP receptor ex-
pression is the thymus (21). Within the thymus, the TP recep-
tor is expressed most highly by immature thymocytes. Ex-
posure of these cells to TXA2 agonists causes apoptosis,
suggesting that TXA2 may play a role in thymic selection (9).
Based on these data, we performed careful analysis of thymic
architecture and cellular composition. Although TP receptor
Figure 5. Hemodynamic effects of the in-
travenous TP receptor agonist U-46619 in-
fusion. Data are expressed as the change 
in MAP compared with baseline, pretreat-
ment values. Black squares represent wild-
type mice (n 5 4), whereas white circles 
represent the Tp2/2 mice. *P # 0.003 vs. 
wild-type.
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agonist binding is not detectable in thymocytes from Tp2/2
mice, the structure of their thymuses is normal by histological
examination. Immunohistochemical staining shows no differ-
ence in the distribution of double (CD41CD81) or single
(CD41 or CD81) staining thymocytes within the thymic cortex
and medulla, respectively. When thymocytes from wild-type
and Tp2/2 mice were analyzed by flow cytometry, we found no
significant differences in their composition or expression of
major cell surface markers. These data suggest that absence of
the TP receptors from thymus does not substantially alter its
structure or cellular composition.
Previously, we used receptor autoradiography to map
TXA2 binding sites within the adult mouse kidney and found
significant numbers of binding sites in both the renal cortex
and medulla (27). Analysis of ligand displacement kinetics re-
vealed distinct high-affinity binding sites in the cortex and a
predominance of low-affinity sites in the renal medulla. Al-
though the human TP gene encodes two isoforms of the TP re-
ceptor (46), we could not detect alternative splicing of the TP
receptor mRNA using RT-PCR. To assess whether there
might be multiple TP receptor isoforms encoded by additional
genes, we performed receptor autoradiography on Tp1/1 and
Tp2/2 mice using the TP receptor agonist 125I-BOP. Neither
cortical nor medullary binding was detected in Tp2/2 mouse
kidney. This suggests that all of these binding sites arise from
the single known Tp gene locus. Thus, we conclude that if TP
receptors in the kidney exist in varying affinity states, they are
still products of a single gene.
TP receptors are also expressed at high levels in platelets.
Stimulation of this receptor causes TXA2 synthesis, and plate-
let activation and aggregation (47). The marked prolongation
of bleeding time in Tp2/2 mice confirms the importance of this
pathway in promoting hemostasis. To determine whether the
bleeding defect in Tp2/2 mice is associated with alterations in
platelet function, we examined platelet aggregation responses
in TP receptor–deficient mice. In wild-type mice, the TP recep-
tor agonist U-46619 causes rapid, irreversible platelet aggrega-
tion. In contrast, platelets from Tp-deficient mice are unre-
sponsive to TP receptor agonist treatment. Thus, disruption of
the known Tp gene locus completely eliminates TXA2-medi-
ated platelet aggregation.
TXA2 may have diverse effects on platelet activation and
aggregation including direct effects of TXA2 binding to the
platelet TP receptor described above. Alternatively, TXA2
may promote platelet aggregation by amplifying activation
signals of less potent agonists (48). To examine the contribu-
tion of TP receptors to other pathways for platelet activation,
we assessed aggregation of Tp2/2 PRP in response to ADP
and collagen. Unlike TXA2, ADP causes a reversible aggrega-
tion profile in mice but does not trigger the platelet release re-
action (49). When PRP from wild-type or Tp2/2 mice was ex-
posed to ADP, there was no significant difference in the
platelet aggregation responses. These results demonstrate
that the TP receptor does not play a significant role in ADP-
induced platelet aggregation in mice. This differs from human
platelets where ADP causes a reversible aggregation followed
by a secondary wave of irreversible aggregation that is depen-
dent on TXA2 (50).
Platelets bind to collagen via the cell surface GpIa-IIa re-
ceptor (a2b1 integrin) (51, 52), and this binding triggers the ac-
tivation of a series of several secondary messenger systems and
results in platelet aggregation (47). A role for the TP receptor
in this process is confirmed by our observation that the interval
between collagen exposure and the onset of platelet aggrega-
tion was prolonged in TP receptor–deficient platelets compared
with controls. Previous studies had suggested that GpIa-IIa re-
ceptor stimulation activates phospholipase A2 which generates
TXA2 augmenting the activation signals from other second
messenger systems (47, 51, 53). Since the maximal aggregation
response was similar between wild-type and Tp2/2 mice, other
activation signals can eventually induce platelet aggregation in
the absence of TP receptors. Furthermore, the preserved max-
imal responses of TP receptor–deficient PRP to ADP and col-
lagen treatment may explain the lack of significant bleeding in
Tp2/2 mice during procedures such as tail biopsy or catheter
placement.
Figure 6. Hemodynamic effects of intrave-
nous arachidonic acid infusion. Data are 
expressed as the change in MAP compared 
with baseline, pretreatment values. Black 
squares represent wild-type mice (n 5 4), 
whereas white circles represent Tp2/2 mice 
(n 5 4). *P # 0.01 vs. Tp2/2 mouse D 
MAP, †P # 0.018 vs. baseline, ‡P # 0.0325 
vs. baseline.
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Intravenous administration of the TXA2 mimetic U-46619
induces a shock syndrome characterized by cardiovascular col-
lapse and sudden death. This syndrome is associated with sys-
temic platelet aggregation, pulmonary thrombosis, and coro-
nary spasm (45, 54, 55) and suggests a role for TXA2 septic
shock. To determine the role of the Tp gene locus in mediating
these effects, we monitored the hemodynamic effect of U-46619
infusion in Tp2/2 and wild-type mice (Fig. 5). In Tp1/1 mice,
the lowest dose of this TP receptor agonist caused transient
vasoconstriction whereas the higher dose induced rapid car-
diovascular collapse. In contrast, infusion of U-46619 had no
detectable effect on systemic hemodynamics in Tp2/2 mice,
suggesting that these actions are mediated exclusively by TP
receptors.
Infusion of arachidonic acid also causes shock and sudden
death (43, 56–58). Similar to the effects of U-46619, Tp2/2 mice
are resistant to hemodynamic collapse induced by arachidonic
acid, demonstrating that the effects of arachidonic acid infu-
sion to induce sudden death are mediated primarily by TP re-
ceptors. Unlike U-46619, which had no detectable effect on
Tp2/2 mice, infusion of arachidonic acid significantly lowered
MAP in Tp2/2 mice. Although the mechanism of this effect is
not clear from our studies, we suggest that this effect may be
caused by enhanced production of vasodilatory eicosanoids
such as prostaglandin E2 and prostaglandin I2 (prostacyclin),
which are produced from arachidonic acid substrate.
In summary, these studies have identified a critical role for
the Tp gene locus in hemostasis and in mediating vascular re-
sponses to arachidonic acid and TXA2 agonists. The absence
of functional TP receptors has no effect on normal develop-
ment or survival. Our studies provide strong evidence that
most of the known functions of TXA2 can be accounted for by
the single known Tp gene locus. These Tp2/2 mice will be valu-
able tools for assessing the role of TP receptors in disease
states.
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